With patents for many NBCDs soon to expire, the need for regulatory guidance regarding follow-on versions of these products is crucial.
Scott Kolodny, MD
Advertisement
Articles by Scott Kolodny, MD
Advertisement
Latest Updated Articles
Safety Considerations for Follow-On Non-Biologic Complex DrugsPublished: June 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
3
AI in Action: Breaking Down Clinical Trial Bottlenecks
4
Unlocking the Potential of Agentic AI to Reduce Trial Delays
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
